Yes, you can still have endometriosis after menopause. While the drop in estrogen that comes with menopause relieves symptoms for most people, endometriosis can persist, recur, or even appear for the first time in postmenopausal women. The condition is less common after menopause, but it’s far from impossible, and it often looks different than it did during your reproductive years.
Why Endometriosis Can Survive Without Periods
The common assumption is that endometriosis depends entirely on the estrogen produced by the ovaries, so once the ovaries wind down at menopause, the disease should disappear. That’s only partly true. After menopause, your ovaries stop being the main source of estrogen, but your body doesn’t stop making it altogether. Adipose (fat) tissue becomes the primary estrogen-producing tissue in postmenopausal women. This lower but steady supply of estrogen can be enough to fuel endometriosis lesions.
Even more striking, endometriosis lesions themselves can produce their own estrogen through an enzyme called aromatase. This creates a self-sustaining loop: the lesions generate estrogen, which triggers local inflammation, which in turn stimulates more aromatase activity and more estrogen. So even in a low-estrogen postmenopausal environment, the disease can maintain itself from within.
How Symptoms Differ After Menopause
Postmenopausal endometriosis tends to present with vague, nonspecific symptoms that are easy to attribute to other conditions. Pelvic pain, ovarian cysts, and intestinal complaints like bloating or bowel changes are the most common signs. Because you’re no longer menstruating, the classic pattern of cyclical pain tied to your period is gone, which can make the connection to endometriosis harder to recognize.
The ovaries are the most common site for postmenopausal endometriosis lesions, accounting for roughly 79% of cases. Outside the pelvis, the gastrointestinal tract is the next most frequent location, particularly the sigmoid colon and rectum. The urinary tract, especially the bladder and ureters, can also be involved. Urinary tract endometriosis is especially tricky to diagnose because its symptoms (urinary urgency, flank pain, blood in urine) overlap with many other conditions common in older women.
Hormone Replacement Therapy and Recurrence
If you had endometriosis before menopause and are now considering hormone replacement therapy (HRT) for hot flashes, night sweats, or other menopausal symptoms, the type of HRT matters significantly. Estrogen-only HRT carries a real risk of reactivating dormant endometriosis. In one retrospective study, 8% of women on estrogen-only therapy experienced recurrence, compared to zero recurrences among women taking combined estrogen-progestin therapy. A systematic review found that 13 out of 14 reported cases of endometriosis recurrence after surgical menopause involved women on estrogen-only HRT.
Because of this pattern, both the British Menopause Society and the European Society of Human Reproduction and Embryology recommend continuous combined HRT (estrogen plus a progestin given daily, not cyclically) for women with a history of endometriosis. This applies even if you’ve had a hysterectomy, which would normally make estrogen-only therapy the standard choice. Some clinicians also prescribe tibolone, a synthetic steroid that has a progestin-like effect on endometrial tissue, as an alternative.
Estrogen-only HRT may only be reasonable in cases where the original endometriosis was mild and was completely removed surgically. Even then, combined therapy is generally the safer bet.
How Postmenopausal Endometriosis Is Diagnosed
Diagnosis can be challenging because postmenopausal endometriosis often mimics ovarian cancer, bowel disease, or urinary conditions on initial evaluation. Pelvic ultrasound is typically the first step and is quite sensitive for detecting ovarian endometriomas (cysts filled with old blood that appear as fluid-filled sacs with a characteristic “ground glass” look) and bowel-invasive disease. MRI offers better anatomic detail and is particularly useful for identifying lesions in multiple locations at once. On MRI, endometriomas show a distinctive “light bulb” brightness on certain sequences due to blood degradation products, while deep lesions appear as dark, fibrous plaques that may contain small cystic areas indicating active glandular disease.
The key concern with any ovarian mass in a postmenopausal woman is ruling out cancer. MRI is especially valuable here because it can characterize the internal features of a cyst and identify signs of malignant transformation that ultrasound might miss.
The Cancer Question
One worry that brings many postmenopausal women to search for this topic is whether old endometriosis lesions can become cancerous. Malignant transformation of endometriosis does occur, but it’s rare, affecting roughly 0.7% to 1.0% of patients with endometriosis. When it happens, it almost always involves endometriosis on the ovarian surface and typically develops into specific subtypes of ovarian cancer (clear cell or endometrioid types).
A large study from the Iowa Women’s Health Study found that a self-reported history of endometriosis was not associated with a higher risk of cancer overall, breast cancer, or ovarian cancer in postmenopausal women. So while the theoretical risk exists and justifies monitoring, it shouldn’t be a source of significant anxiety. Any recurrence of symptoms in a postmenopausal woman with a history of endometriosis does warrant thorough evaluation, both to manage the disease itself and to rule out other causes.
Treatment Options After Menopause
Treatment for postmenopausal endometriosis differs from the approaches used during reproductive years. Many of the standard premenopausal treatments, like birth control pills or medications that suppress ovarian function, don’t make sense when the ovaries are already inactive. Instead, treatment targets the extra-ovarian estrogen that’s keeping the disease alive.
Aromatase inhibitors are the most relevant medical option. These drugs block the enzyme responsible for estrogen production in fat tissue and within the endometriosis lesions themselves, cutting off both sources of fuel. In clinical studies, aromatase inhibitors reduced pain in all treated patients and shrank the size of lesions on imaging. They also improved urinary and gastrointestinal symptoms associated with endometriosis in those locations. One limitation: lesions with significant scar tissue (fibrosis) may not respond to medication alone. In one reported case, ureteral endometriosis with heavy fibrosis required surgery despite 15 months of aromatase inhibitor therapy.
Surgery remains an option for lesions that don’t respond to medication, for large ovarian endometriomas, or when cancer needs to be ruled out. The choice between medical and surgical management depends on symptom severity, lesion location, your overall health, and your own preferences after a thorough discussion of the trade-offs.